Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone H2B type 1-N (H2BC15) is a core component of the nucleosome, the primary structural unit of chromatin in eukaryotic cells[1][2][5][6]. Two molecules each of H2A, H2B (including H2B type 1-N), H3, and H4 form an octamer around which DNA is wrapped to form nucleosomes; these structures compact DNA, regulate DNA accessibility, and play key roles in chromatin organization, transcription regulation, DNA repair, DNA replication, and chromosomal stability[1][2][6]. This particular H2B is encoded by the intronless *HIST1H2BN* gene, located in a histone gene cluster on human chromosome 6p22-p21.3, and is expressed as a replication-dependent histone[2][1]. Post-translational modifications of H2B (such as ubiquitination) are critical for its functions in regulating chromatin dynamics and downstream histone marks[3][6]. Diseases associated with deregulation of H2B proteins include cancer and autoimmune diseases like systemic lupus erythematosus[1][2]. No approved drugs are known to specifically target H2BC15 directly[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone H2B type 1-N (H2BC15).